Vigil Neuroscience Inc. Announces Merger with Sanofi; Definitive Proxy Statement Filed with SEC

Reuters07-28

Vigil Neuroscience Inc. Announces Merger with <a href="https://laohu8.com/S/GCVRZ">Sanofi</a>; Definitive Proxy Statement Filed with SEC

Vigil Neuroscience, Inc., a Delaware corporation, has announced an update regarding its merger with Sanofi, a French société anonyme. As per the Agreement and Plan of Merger, Sanofi's wholly-owned subsidiary, Vesper Acquisition Sub Inc., will merge with Vigil, with Vigil continuing as a wholly-owned subsidiary of Sanofi. The company filed a definitive proxy statement with the SEC concerning the merger on June 30, 2025. Additionally, Vigil has voluntarily provided supplemental disclosures to address certain litigation matters related to the merger. No new agreements have been made with Parent for the post-merger employment of Vigil's executive officers as of July 28, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigil Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-165862), on July 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2554751007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554751007","market":"us","top_or_hot":-1,"title":"Vigil Neuroscience Inc. Announces Merger with Sanofi; Definitive Proxy Statement Filed with SEC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vigil Neuroscience Inc. Announces Merger with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>; Definitive Proxy Statement Filed with SEC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VIGL\">Vigil Neuroscience, Inc.</a>, a <a href=\"https://laohu8.com/S/VMM\">Delaware</a> corporation, has announced an update regarding its merger with <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>, a French société anonyme. As per the Agreement and Plan of Merger, Sanofi's wholly-owned subsidiary, Vesper Acquisition Sub Inc., will merge with Vigil, with Vigil continuing as a wholly-owned subsidiary of Sanofi. The company filed a definitive proxy statement with the SEC concerning the merger on June 30, 2025. Additionally, Vigil has voluntarily provided supplemental disclosures to address certain litigation matters related to the merger. No new agreements have been made with Parent for the post-merger employment of Vigil's executive officers as of July 28, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigil Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-165862), on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigil Neuroscience Inc. Announces Merger with Sanofi; Definitive Proxy Statement Filed with SEC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigil Neuroscience Inc. Announces Merger with Sanofi; Definitive Proxy Statement Filed with SEC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 19:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vigil Neuroscience Inc. Announces Merger with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>; Definitive Proxy Statement Filed with SEC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VIGL\">Vigil Neuroscience, Inc.</a>, a <a href=\"https://laohu8.com/S/VMM\">Delaware</a> corporation, has announced an update regarding its merger with <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>, a French société anonyme. As per the Agreement and Plan of Merger, Sanofi's wholly-owned subsidiary, Vesper Acquisition Sub Inc., will merge with Vigil, with Vigil continuing as a wholly-owned subsidiary of Sanofi. The company filed a definitive proxy statement with the SEC concerning the merger on June 30, 2025. Additionally, Vigil has voluntarily provided supplemental disclosures to address certain litigation matters related to the merger. No new agreements have been made with Parent for the post-merger employment of Vigil's executive officers as of July 28, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigil Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-165862), on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIGL","symbol_name":"Vigil Neuroscience, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL9Q7ytC:1","article_id":"2554751007","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554751007","pubTimestamp":1753701339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vigil Neuroscience, Inc., a Delaware corporation, has announced an update regarding its merger with Sanofi, a French société anonyme. As per the Agreement and Plan of Merger, Sanofi's wholly-owned subsidiary, Vesper Acquisition Sub Inc., will merge with Vigil, with Vigil continuing as a wholly-owned subsidiary of Sanofi. The company filed a definitive proxy statement with the SEC concerning the merger on June 30, 2025. Additionally, Vigil has voluntarily provided supplemental disclosures to address certain litigation matters related to the merger. No new agreements have been made with Parent for the post-merger employment of Vigil's executive officers as of July 28, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigil Neuroscienc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIGL":"Vigil Neuroscience, Inc.","BK4139":"生物科技"},"translate_title":"Vigil Neuroscience Inc.宣布与赛诺菲合并；向SEC提交的最终委托书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIGL":0.9},"content_text":"Vigil Neuroscience Inc. Announces Merger with Sanofi; Definitive Proxy Statement Filed with SEC\n    \n\nVigil Neuroscience, Inc., a Delaware corporation, has announced an update regarding its merger with Sanofi, a French société anonyme. As per the Agreement and Plan of Merger, Sanofi's wholly-owned subsidiary, Vesper Acquisition Sub Inc., will merge with Vigil, with Vigil continuing as a wholly-owned subsidiary of Sanofi. The company filed a definitive proxy statement with the SEC concerning the merger on June 30, 2025. Additionally, Vigil has voluntarily provided supplemental disclosures to address certain litigation matters related to the merger. No new agreements have been made with Parent for the post-merger employment of Vigil's executive officers as of July 28, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigil Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-165862), on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554751007","isCrawlerRequest":true}